Betamethasone acetate

Betamethasone acetate is a glucocorticoid with prenatal application for preventing respiratory distress syndrome (RDS) in premature infants. Betamethasone acetate exhibits dose-dependent effects on somatic and brain development in offspring when administered prenatally to pregnant rats. Betamethasone acetate can be used for the study of antenatal intervention[1][2].

Product Specifications

CAS Number

[987-24-6]

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Glucocorticoid Receptor

Type

Reference compound

Related Pathways

Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/betamethasone-acetate.html

Purity

99.38

Solubility

10 mM in DMSO

Smiles

C[C@@]12[C@](C[C@H](C)[C@]2(O)C(COC(C)=O)=O)([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C1)=O

Molecular Formula

C24H31FO6

Molecular Weight

434.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Schmidt AF, et al. Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep. Am J Obstet Gynecol. 2018 Jan;218 (1) :132.e1-132.e9.|[2]Scheepens A, et al. A single course of prenatal betamethasone in the rat alters postnatal brain cell proliferation but not apoptosis. J Physiol. 2003 Oct 1;552 (Pt 1) :163-75.